Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Open HLN dashboard ↗Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Open JAGX dashboard ↗